Newamsterdam Pharma CO NV 10-Q quarterly reports

NewAmsterdam Pharma Company N.V. reported its second-quarter 2026 financial results, showing a significant decrease in revenue and an increase in net loss, while advancing its obicetrapib development programs.

NewAmsterdam Pharma reports Q1 2026 results with ongoing clinical trials for obicetrapib, a potential LDL-C lowering therapy, and European regulatory reviews progressing.

NewAmsterdam Pharma reported a significant increase in net loss for Q3 2025, driven by decreased revenue and warrant fair value changes, despite reduced R&D expenses.

NewAmsterdam Pharma reported a significant reduction in net loss for Q2 2025, driven by increased license revenue and decreased R&D expenses, alongside positive Alzheimer's disease biomarker data for obicetrapib.

NewAmsterdam Pharma reports its financial results for the first quarter of 2025, highlighting revenue from its Menarini license and progress in clinical development.

NewAmsterdam Pharma announced positive topline results from its Phase 3 BROOKLYN trial and provided a financial update for the quarter ended September 30, 2024.

NewAmsterdam Pharma's Q2 2024 report details financial results, progress in clinical trials, and a strengthened cash position, while also noting ongoing risks and challenges.

NewAmsterdam Pharma reported a net loss of $93.8 million for the first quarter of 2024, while also highlighting the progress of its Phase 3 clinical trials for obicetrapib.